Display options
Cite
Treuer T, Méndez L, Montgomery W, et al. Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review. Neuropsychiatr Dis Treat. 2016;12:1061-83doi: 10.2147/NDT.S97724.
Treuer, T., Méndez, L., Montgomery, W., & Wu, S. (2016). Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review. Neuropsychiatric disease and treatment, 121061-83. https://doi.org/10.2147/NDT.S97724
Treuer, Tamás, et al. "Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review." Neuropsychiatric disease and treatment vol. 12 (2016): 1061-83. doi: https://doi.org/10.2147/NDT.S97724
Treuer T, Méndez L, Montgomery W, Wu S. Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review. Neuropsychiatr Dis Treat. 2016 May 03;12:1061-83. doi: 10.2147/NDT.S97724. eCollection 2016. PMID: 27217754; PMCID: PMC4862343.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2016 May 03;12:1061-83. doi: 10.2147/NDT.S97724. eCollection 2016.

Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review.

Neuropsychiatric disease and treatment

Tamás Treuer, Luis Méndez, William Montgomery, Shenghu Wu

Affiliations

  1. Neuroscience Research, Eli Lilly and Company, Budapest, Hungary.
  2. Eli Lilly de Mexico, Mexico City, Mexico.
  3. Global Patient Outcomes and Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia.
  4. Neuroscience Research, Eli Lilly Asia, Inc, Shanghai, People's Republic of China.

PMID: 27217754 PMCID: PMC4862343 DOI: 10.2147/NDT.S97724

Abstract

The purpose of this paper was to systematically review the literature related to research about the factors affecting treatment adherence and discontinuation of atomoxetine in pediatric, adolescent, and adult patients with attention-deficit/hyperactivity disorder (ADHD). Medline was systematically searched using the following prespecified terms: "ADHD", "Adherence", "Compliance", "Discontinuation", and "Atomoxetine". We identified 31 articles that met all inclusion and exclusion criteria. The findings from this review indicate that persistence and adherence to atomoxetine treatment were generally high. Factors found to influence adherence and nonadherence to atomoxetine treatment in ADHD in this review include age, sex, the definition of response used, length of treatment, initial dose of treatment, comorbid conditions, and reimbursement. Tolerability was cited as an important reason for treatment discontinuation. More research is needed to understand those factors that can help to identify patients at risk for poor adherence and interventions that could improve treatment adherence early in the stage of this illness to secure a better long-term prognosis.

Keywords: ADHD medication; adherence; atomoxetine; compliance; relapse; treatment discontinuation

References

  1. J Psychosom Res. 1999 Dec;47(6):555-67 - PubMed
  2. Ann Clin Psychiatry. 2009 Jan-Mar;21(1):26-37 - PubMed
  3. Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):791-815 - PubMed
  4. Am J Manag Care. 2009 May;15(5 Suppl):S141-50 - PubMed
  5. Curr Pharm Des. 2010;16(22):2416-23 - PubMed
  6. Depress Anxiety. 2009;26(3):212-21 - PubMed
  7. J Psychopharmacol. 2015 Dec;29(12):1221-30 - PubMed
  8. J Child Adolesc Psychopharmacol. 2014 Nov;24(9):472-80 - PubMed
  9. Patient Prefer Adherence. 2013 Sep 30;7:987-95 - PubMed
  10. Int J Clin Pract. 2014 Sep;68(9):1152-60 - PubMed
  11. Contemp Fam Ther. 2007 Jun;29(1-2):39-55 - PubMed
  12. J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):896-904 - PubMed
  13. Pediatr Transplant. 2008 May;12(3):289-99 - PubMed
  14. Postgrad Med. 2008 Sep;120(3):48-59 - PubMed
  15. Psychiatry Clin Neurosci. 2011 Feb;65(1):55-63 - PubMed
  16. J Clin Psychopharmacol. 2004 Feb;24(1):30-5 - PubMed
  17. Clin Child Fam Psychol Rev. 2012 Sep;15(3):215-33 - PubMed
  18. J Can Acad Child Adolesc Psychiatry. 2006 May;15(2):75-83 - PubMed
  19. Harv Rev Psychiatry. 2008;16(2):126-35 - PubMed
  20. Atten Defic Hyperact Disord. 2015 Jun;7(2):165-74 - PubMed
  21. Value Health. 2008 Jan-Feb;11(1):44-7 - PubMed
  22. N Engl J Med. 2005 Aug 4;353(5):487-97 - PubMed
  23. J Child Adolesc Psychopharmacol. 2012 Dec;22(6):452-8 - PubMed
  24. J Pediatr Psychol. 2001 Jul-Aug;26(5):277-8 - PubMed
  25. Postgrad Med. 2012 May;124(3):139-48 - PubMed
  26. Patient Prefer Adherence. 2014 Sep 25;8:1317-27 - PubMed
  27. Curr Med Res Opin. 2011;27 Suppl 2:13-22 - PubMed
  28. Patient Educ Couns. 2010 Mar;78(3):350-6 - PubMed
  29. Asia Pac Psychiatry. 2014 Dec;6(4):386-96 - PubMed
  30. Expert Opin Pharmacother. 2009 Mar;10(4):669-76 - PubMed
  31. Biol Psychiatry. 2007 Mar 1;61(5):694-9 - PubMed
  32. J Child Adolesc Psychopharmacol. 2012 Apr;22(2):139-48 - PubMed
  33. J Child Adolesc Psychopharmacol. 2006 Jun;16(3):286-97 - PubMed
  34. Paediatr Drugs. 2007;9(5):283-8 - PubMed
  35. Epilepsy Behav. 2011 Jan;20(1):95-102 - PubMed
  36. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24 - PubMed
  37. J Clin Psychiatry. 2013 Jan;74(1):e87-93 - PubMed
  38. Health Qual Life Outcomes. 2013 Feb 22;11:22 - PubMed
  39. Curr Med Res Opin. 2010 Apr;26(4):977-89 - PubMed
  40. Clin Ther. 2011 Feb;33(2):188-203 - PubMed
  41. Eur Psychiatry. 2011 Apr;26(3):166-75 - PubMed
  42. Curr Psychiatry Rep. 2013 Jul;15(7):371 - PubMed
  43. Ther Adv Psychopharmacol. 2013 Apr;3(2):65-71 - PubMed
  44. J Am Acad Child Adolesc Psychiatry. 2007 May;46(5):566-72 - PubMed
  45. J Med Econ. 2013 Nov;16(11):1275-89 - PubMed
  46. Eur Child Adolesc Psychiatry. 2009 Apr;18(4):240-9 - PubMed
  47. Am J Addict. 2009 Sep-Oct;18(5):393-401 - PubMed
  48. Transplantation. 2007 Oct 27;84(8):1052-4 - PubMed
  49. Open Med. 2009;3(3):e123-30 - PubMed
  50. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):831-9 - PubMed
  51. Acta Psychiatr Scand. 2013 Jul;128(1):70-7 - PubMed
  52. J Med Econ. 2013 Jul;16(7):962-75 - PubMed
  53. Asia Pac Psychiatry. 2014 Mar;6(1):62-70 - PubMed
  54. Neurology. 2005 Dec 27;65(12):1941-9 - PubMed
  55. Eur Neuropsychopharmacol. 2013 Dec;23(12):1732-8 - PubMed
  56. Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011 - PubMed
  57. J Allergy Clin Immunol. 1996 Dec;98(6 Pt 1):1051-7 - PubMed
  58. J Child Adolesc Psychopharmacol. 2009 Dec;19(6):673-81 - PubMed
  59. Eur J Clin Pharmacol. 2013 Mar;69(3):589-98 - PubMed
  60. Clin Neuropharmacol. 2011 Mar-Apr;34(2):51-60 - PubMed
  61. Pediatrics. 2005 Jun;115(6):e718-24 - PubMed
  62. Clin Pediatr (Phila). 2015 Feb;54(2):164-73 - PubMed
  63. J Pediatr Psychol. 2008 Sep;33(8):867-74 - PubMed
  64. J Psychopharmacol. 2015 Jan;29(1):3-14 - PubMed
  65. Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):349-53 - PubMed

Publication Types